Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same

A technology of lamivudine and composition, which is applied in the field of treating patients with liver diseases, and can solve problems such as hepatic necrosis, inflammation deterioration, hepatic decompensation or cirrhosis, and reactivation

Inactive Publication Date: 2005-03-23
邬之盛
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Sometimes, continued treatment leads to repeated exacerbations of hepatonecroinflammation, which leads to hepatic decompensation or cirrhosis; on the other hand, cessation of treatment can lead to reactivation of wild-type virus, which also leads to exacerbation of hepatonecroinflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
  • Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] pharmaceutical preparations

[0067] The kinds and amounts of the herbal ingredients used in the method of preparing the pharmaceutical composition of the present invention are described in Table 2. This pharmaceutical composition is called "YGK". It can be formulated as injection and capsule.

[0068] components

Weight (kg)

components

Weight (kg)

Hedyotis diffusa

2.49

Notoginseng

0.83

Ginseng

2.49

Red ginseng

0.83

Knotweed

0.83

Scrophulariaceae

1.66

Northern Bean Roots

0.83

Schisandra

1.66

Scutellaria baicalensis

0.83

turmeric

0.83

bezoar powder

0.083

hawthorn

1.66

Astragalus

1.66

angelica

0.83

Wolfberry

2.49

[0069] (1) Quality control of raw materials

[0070] Quality control tests were performed on each individual raw material fo...

Embodiment 2

[0184] Therapeutic Efficacy of YGK Herbal Composition on Patients with Hepatitis B (HBV)

[0185] The clinical study was carried out at the 211 Hospital of the Chinese People's Liberation Army. There are many causes of hepatitis B, including immune response, host genetic factors, and HBV mutations. Chronic hepatitis is different from acute hepatitis. Acute hepatitis is an active and symptomatic infection of the liver. Patients with acute hepatitis are contagious. Symptoms of acute HBV infection are nonspecific but may include malaise, anorexia, or jaundice. Patients with chronic hepatitis are asymptomatic. HBV is present in the liver and blood, although there are usually no obvious physical symptoms. Specific blood tests will show the presence of the virus, and patients are also infected through blood, childbirth, sex, needles, etc. Liver cirrhosis is a pathological dysfunctional state of the liver, caused by chronic hepatitis, chronic persistent hepatitis (CPH) and ch...

Embodiment 3

[0199] Toxicity Study of YGK Herbal Composition in Animals

[0200] Purpose:

[0201] The following experiments were conducted in the Toxicology Laboratory of the Institute of Occupational Health and Occupational Diseases of Heilongjiang Province, China, to examine the acute toxicity of the YGK herbal composition during intravenous injection in animals.

[0202] method:

[0203] The experimental animals were Japanese white-eared rabbits obtained from the Animal Center of Harbin Medical University, Heilongjiang Province, China. This species of rabbits is characterized by clear blood vessels in the ears, and the experiment is easy to operate.

[0204] Obtain 10 above-mentioned domestic rabbits, six males and four females, each weighing between 1900 grams and 3000 grams.

[0205] The rabbits were randomly divided into two groups, five in each group, including two female rabbits and three male rabbits. The two groups of animals were intravenously injected with th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for treating patients with liver diseases by co-administrating a pharmaceutical composition and lamivudine to the patients. The pharmaceutical composition is a herbal mixture which contains, as the core ingredients, the aqueous extracts of the entire plant of Herba Hedyotidis diffusae, the rhizome of Rhizoma Bistortae, the rhizome of Rhizoma Polygoni Cuspidati, and the ripe fruit of Fructus Schisandrae. The present invention also provides methods for preventing a relapse of hepatitis in patients after the lamivudine treatment has been discontinued and for suppressing the development of lamivudine drug resistance in patients by providing the lamivudine-treated patients with the pharmaceutical composition of the present invention.

Description

technical field [0001] The present invention relates to a method for treating patients with liver disease, which comprises administering to the patient a prescription comprising the pharmaceutical composition and lamivudine. The pharmaceutical composition comprises the whole plant of Hedyotidisdiffusae (Herba Hedyotidisdiffusae), the rhizome of Rhizoma Bistoriae, the rhizome of Rhizoma Polygoni Cuspidali, and the aqueous extract of ripe fruit of Fructus Schisandrae as core ingredients . The present invention also relates to methods of preventing relapse of liver disease and inhibiting the development of lamivudine resistance by administering the pharmaceutical composition of the present invention to a patient. Background of the invention [0002] Viral hepatitis is a major entero-transmitted liver disease caused by viral infection. The main route of transmission of the disease is through ingestion; viral hepatitis is also transmitted by transfusion of virus-contaminated bl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7068A61K35/37A61K35/413A61K36/232A61K36/258A61K36/481A61K36/538A61K36/539A61K36/59A61K36/70A61K36/704A61K36/734A61K36/748A61K36/79A61K36/808A61K36/815A61K36/9066
CPCA61K35/413A61K36/808A61K36/748A61K36/734A61K36/538A61K36/539A61K36/79A61K36/481A61K36/704A61K36/258A61K36/232A61K36/59A61K36/9066A61K31/7068A61K36/815A61K36/70A61K2300/00
Inventor 邬之盛
Owner 邬之盛
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com